Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
NASA launches science balloon in Antarctica | Space photo of the day for Dec. 22, 2025 - 2French ship crosses Strait of Hormuz in first Western European transit during Iran war
- 3This Week In Space podcast: Episode 187 — An Inspired Enterprise
- 4The risk of falling space junk hitting airplanes is on the rise, experts warn
- 5Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach'
- Venezuelans in Madrid celebrate Maduro's capture
- Putting pig organs in people is OK in the US, but growing human organs in pigs is not – why is that?
- She was moments away from giving birth. The hospital discharged her
- Top Pastry: What's Your Sweet Treat of Decision?
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- Parents speak out as 4-year-old fights button battery injury in intensive care unit
- Vote In favor of Your Number one Savvy Beds
- Promising Speculation Bearings for Portfolio Development in 2024
- James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
